Sugi Predict

Sugi Predict / Targets / NPY5R

NPY5R

Neuropeptide Y receptor type 5 · Q15761 · NPY5R on Sugi Atlas →

112,212 patent compounds predicted against NPY5R, 56,012 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL175710 SCHEMBL175710 1.00 19/20
Cgp-71683A Cgp-71683A (SCHEMBL326665) 1.00 19/20
Cgp-71683A Cgp-71683A (SCHEMBL225992) 0.98 19/20
SCHEMBL38332 SCHEMBL38332 0.55 19/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL225991) 0.62 18/20
Tiaramide Tiaramide (SCHEMBL25172) 0.58 16/20
Tiaramide Tiaramide (SCHEMBL181916) 0.58 16/20
SCHEMBL171980 SCHEMBL171980 0.49 13/20
SCHEMBL241711 SCHEMBL241711 0.64 10/20
SCHEMBL241712 SCHEMBL241712 0.64 10/20
SCHEMBL335529 SCHEMBL335529 0.51 10/20
Leupeptin Leupeptin (SCHEMBL25361) 0.51 10/20
SCHEMBL334075 SCHEMBL334075 0.50 10/20
SCHEMBL171983 SCHEMBL171983 0.46 9/20
SCHEMBL268329 SCHEMBL268329 0.73 8/20
SCHEMBL268375 SCHEMBL268375 0.69 8/20
SCHEMBL238214 SCHEMBL238214 0.69 8/20
Kyotorphin Kyotorphin (SCHEMBL248288) 0.62 8/20
Kyotorphin Kyotorphin (SCHEMBL248289) 0.62 8/20
Acetic Acid Acetic Acid (SCHEMBL230814) 0.55 8/20

Clinical trials — most relevant to NPY5R by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Medication, Weight Gain and GI Hormones PHASE4COMPLETED
Saxenda: Underlying Mechanisms and Clinical Outcomes PHASE4ACTIVE_NOT_RECRUITING
Prevention of Obesity in Women Via Estradiol Regulation PHASE3COMPLETED
Effects of Exenatide on Hypothalamic Obesity PHASE1/PHASE2COMPLETED
Intranasal Administration of Neuropeptide Y in Healthy Male Volunteers PHASE2COMPLETED
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment PHASE1/PHASE2RECRUITING
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin PHASE2UNKNOWN
Intranasal Neuropeptide Y in Clinical Trial in Level Two Trauma Patients for PTSD and Acute Stress Disorder PHASE1/PHASE2UNKNOWN
Degradation of the Anorexic Hormone Peptide YY EARLY_PHASE1COMPLETED
Neuropeptide Y and Sympathovagal Balance EARLY_PHASE1COMPLETED
In Vitro Studies on Pharmacological Regulation and Genetic Risk Factors of Peripheral Human Nociceptors nanCOMPLETED
Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma nanCOMPLETED
Auricular Vagus Stimulation in Obesity nanACTIVE_NOT_RECRUITING
Shiatsu Adjuvant Therapy For Schizophrenia nanCOMPLETED
Functional MRI Evaluation of Brain Response to Visual Food Stimulation in Morbidly Obese Patients Before and After Bariatric Surgery nanCOMPLETED
Examination of Brain Serotonin Receptors in Patients With Mood Disorders nanCOMPLETED
The Effect of Weekly Semaglutide Treatment on Energy Expenditure nanCOMPLETED
Macronutrient Regulation of Ghrelin and Peptide YY nanCOMPLETED
RCT to Describe the Effects of Colon Delivered Acetate, Propionate and Butyrate on Satiety and Glucose Homeostasis nanCOMPLETED
Acylated Ghrelin Response to Acute Exercise in Obesity nanCOMPLETED
Investigating Optimal Propionate Delivery to the Colon Using Stable Isotope Labeling nanCOMPLETED
Brain-Derived Neurotrophic Factor in Obesity and Brain Function nanCOMPLETED
Effect of Fermentable Carbohydrate on Glucose Homeostasis nanCOMPLETED
Colonic Propionate, Appetite, and Weight Loss nanCOMPLETED
Gastrointestinal Hormonal Regulation of Obesity nanCOMPLETED
The Progress of Diabetes After Supaglutide Treatment in Type 2 Diabetes Patients nanRECRUITING
Neuropeptide Y (NPY) Regulation of Nociceptors nanCOMPLETED
The Role of Peptide YY (PYY)in Inhibiting Food Intake. nanCOMPLETED
Sex Differences in Neuropeptide Y Serum, But Not in Fat Intake and Body Mass Index nanCOMPLETED
Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a NPY5R binder may also engage these)

ProteinNameSimilarity
O62729 — 1.000 O62729 →
Q63634 — 1.000 Q63634 →
O70342 — 0.999 O70342 →
O97969 — 0.997 O97969 →
P18901 — 0.992 P18901 →
P50130 — 0.990 P50130 →
P42288 — 0.990 P42288 →
DRD1 D(1A) dopamine receptor 0.989 landscape →
Q95136 — 0.989 Q95136 →
Q16950 — 0.989 Q16950 →
P42289 — 0.988 P42289 →
O42384 — 0.988 O42384 →
DRD2 D(2) dopamine receptor 0.988 landscape →
P42290 — 0.987 P42290 →
Q19084 — 0.987 Q19084 →
P52702 — 0.987 P52702 →
P60026 — 0.987 P60026 →
O77680 — 0.986 O77680 →
Q18534 — 0.986 Q18534 →
P31390 — 0.986 P31390 →
Q61616 — 0.986 Q61616 →
O73810 — 0.986 O73810 →
Q02152 — 0.985 Q02152 →
Q15760 — 0.985 Q15760 →
Q16951 — 0.985 Q16951 →
Q18179 — 0.985 Q18179 →
Q91081 — 0.985 Q91081 →
Q61121 — 0.984 Q61121 →
P42291 — 0.984 P42291 →
Q8ITC7 — 0.984 Q8ITC7 →